Disease/Infection News

RSS
Merck signs two licensing agreements for investigational HIV drug candidates

Merck signs two licensing agreements for investigational HIV drug candidates

Little evidence exists for potential HPV type competition in cross-sectional study

Little evidence exists for potential HPV type competition in cross-sectional study

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

Researchers discover bats as reservoir of infections

Researchers discover bats as reservoir of infections

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

Scientists discover structure and operating procedures of anti-bacterial killing machine

Scientists discover structure and operating procedures of anti-bacterial killing machine

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Recent release: Examining next steps for corporate responsibility programs in India

Recent release: Examining next steps for corporate responsibility programs in India

Recent release: World Bank discussion addresses AIDS spending in resource-constrained environment

Recent release: World Bank discussion addresses AIDS spending in resource-constrained environment

Recent release: CSIS blog posts highlight panel discussions on PEPFAR, examine challenges to administering treatment-as-prevention

Recent release: CSIS blog posts highlight panel discussions on PEPFAR, examine challenges to administering treatment-as-prevention

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

Most Indian female sex workers do not disclose HIV serostatus to sex partners

Most Indian female sex workers do not disclose HIV serostatus to sex partners

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

Novel combination drug regimen could be more effective than existing treatments for TB

Novel combination drug regimen could be more effective than existing treatments for TB

International AIDS conference kicks off in Washington, D.C.

International AIDS conference kicks off in Washington, D.C.

First results from community HIV testing campaign in Uganda

First results from community HIV testing campaign in Uganda

Sex workers hold AIDS 2012 'hub' conference in Kolkata, India

Sex workers hold AIDS 2012 'hub' conference in Kolkata, India

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.